Abstract
Autologous bone marrow transplantation (ABMT) is a promising therapeutic modality which is currently under investigation in patients in first complete remission [1–4] as well as those who have attained a subsequent remission following relapse [5,6]. Current results from these studies suggest that remissions are durable in a significant proportion of patients with AML following consolidation with marrow ablative cytotoxic regimens and ABMT. The advantages of ABMT over allogeneic BMT are that donor selection is not needed and thus that the restrictions of the availability of HLA matched donors do not apply. In addition, the age limitations in ABMT are far less stringent, i.e., ABMT can probably be applied in recipients up to 60 years of age. The principal drawback of ABMT is the higher probability of relapse following transplantation and this accounts for most failures and mortality after ABMT in patients with AML. Relapse is attributed to (a) the absence of a graft-versus-leukemia effect in autotransplantation (which appears to protect against relapse after allogeneic marrow transplantation) and (b) the use of autologous bone marrow grafts containing residual leukemia. The latter factor implies that in the further development of ABMT it will be important to identify these residual AML cells and to remove them.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Burnett AK, Tansey P, Watkins R et al. Transplantation of unpurged autologous bone marrow in acute myeloid leukemia in first remission. Lancet 1984;i:1068–70.
Löwenberg B, Abels J, van Bekkum DW et al. Transplantation of non-purified autologous bone marrow in patients with AML in first remission. Cancer 1984; 54:2840–3.
Löwenberg B, Hagenbeek A, Sizoo W, de Gast GC, Verdonck LF. Bone marrow transplantation strategies in acute leukemia. Lancet 1984;ii:1400–1.
Burnett AK, McKinnon S. Autologous bone marrow transplantation in first remission AML using non purged marrow - update. In: Hagenbeek A, Löwenberg B (eds). Minimal residual disease in acute leukemia. Dordrecht: Martinus Nijhoff Publishers 1986:211–21.
Yeager AM, Kaizer H, Santos GW et al. Autologous bone marrow transplantation in patients with acute non-lymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986;315:141–7.
Hervé P, Tamayo E, Chan JY, Plouvier E, Flesch M, Peters A. Attempts to eliminate residual acute myeloid leukemia from autologous bone marrow grafts through in vitro chemotherapy. A review. In: Hagenbeek A, Löwenberg B (eds). Minimal residual disease in actue leukemia. Dordrecht: Martinus Nijhoff Publishers 1986:248–66.
Lange B, Ferrero D, Pessano S et al. Surface phenotype of clonogenic cells in acute myeloid leukemia defined by monoclonal antibodies. Blood 1984;64: 693–700.
Sabbath KD, Ball ED, Larcom P, Davis RB, Griffin JD Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 1985;75:746–53.
Löwenberg B, Bauman JGS. Further results in understanding the subpopulation structure in AML: clonogenic cells and their progeny identified by differentiation markers. Blood 1985;66:1225–32.
Wouters R, Löwenberg B. On the maturation order of AML cells: a distinction on the basis of self-renewal properties and immunologic phenotypes. Blood 1984; 63:684–9.
Touw IP, Löwenberg B. Variable differentiation of human acute myeloid leukemia during colony formation in vitro. A membrane marker analysis with monoclonal antibodies. Brit J Haemat 1985;59:37–44.
Löwenberg B, Swart K, Hagemeijer A. PHA-induced colony formation in acute non-lymphocytic and chronic myeloid leukemia. Leuk Res 1980;4:143–9.
Löwenberg B, Hagemeijer A, Swart K. Karyotypically distinct subpopulations in acute leukemia with specific growth requirements. Blood 1982;59:641–5.
Swart K, Hagemeijer A, Löwenberg B. Acute myeloid leukemia colony growth in vitro: differences of colony forming cells in PHA-supplemented and standard leukocyte feeder cultures. Blood 1982;59:816–21.
Deiwel HR, Touw IP, Löwenberg B. A fucose binding lectin (UEA) for characterizing acute myeloid leukemia progenitor cells. Blood 1985;68:41–5.
Majdic O, Bettelheim P, Stockinger H et al. M2, a novel myelomonocytic cell surface antigen and its distribution on leukemic cells. Int J Cancer 1984;33:617–23.
Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-la cells. J Immunol 1984;133:157–65.
Bodger MP, Francis GE, Delia D, Granger SM, Janossy G. A monoclonal antibody specific for immature human hemopoietic cells and T lineage cells. J Immunol 1981;127:2269–74.
Delwel R, Bot F, Touw IP, Löwenberg B. Exceptional phenotypes of progenitors in acute myelocytic leukemia (AML-CFU): possibilities for separating AML-CFU from normal marrow progenitors. Cancer Res 1987 (in press).
Griffin JD, Löwenberg B. Clonogenic cells in acute myeloblastic leukemia. 1986; 68:1185–95.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Löwenberg, B., Delwel, R. (1987). Autologous Bone Marrow Transplantation in Acute Myeloblastic Leukemia (AML): In Vitro Studies to Detect Minimal Disease in Remission Marrow. In: Sibinga, C.T.S., Das, P.C., Engelfriet, C.P. (eds) White cells and platelets in blood transfusion. Developments in Hematology and Immunology, vol 19. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2089-0_9
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2089-0_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9238-8
Online ISBN: 978-1-4613-2089-0
eBook Packages: Springer Book Archive